Godlewski Grzegorz, Schlicker Eberhard, Baranowska Urszula, Malinowska Barbara
Zakład Fizjologii Doświadczalnej, Akademia Medyczna w Białymstoku, ul. Mickiewicza 2A, PL-15-089 Białystok, Poland.
Shock. 2006 Nov;26(5):510-5. doi: 10.1097/01.shk.0000228794.95302.c3.
A supersensitivity of the beta-adrenoceptor-mediated chronotropic response has been demonstrated in atria isolated from rats subjected to septic shock. Our study was undertaken to investigate whether bacterial endotoxin/LPS affects the increase in heart rate induced by beta-adrenoceptor agonists in the rat also in vivo. In pithed and vagotomized rats, the nonselective beta-adrenoceptor agonist isoprenaline (0.05-0.15 nmol/kg) and agonists at the high- and low-affinity state of beta1-adrenoceptors, that is, prenalterol (0.3-3 nmol/kg) and (+/-)-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazole-2-one (CGP 12177; 3-6 nmol/kg), respectively, and at beta2-adrenoceptors, that is, fenoterol (1-5 nmol/kg), increased heart rate by 50 to 60 beats/min. Administration of LPS (0.4, 1, and 1.5 mg/kg), under continuous infusion of vasopressin, dose-dependently amplified the chronotropic response to isoprenaline, prenalterol, and fenoterol (by 80%, 50%, and 100%, respectively) but not to CGP 12177. The beta2-adrenoceptor antagonist erythro-(+/-)-1-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol (ICI 118551 0.1 mumol/kg) did not affect the chronotropic responses of isoprenaline, fenoterol, and prenalterol under non-endotoxic conditions, but abolished the potentiation of tachycardia produced by LPS (1.5 mg/kg). The beta1-adrenoceptor antagonist (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]-phenoxy]propyl]-amino]ethoxy]-benzamide CGP 20712A; 0.1 mumol/kg almost completely reduced the chronotropic effects of isoprenaline, fenoterol, and prenalterol both in control rats and in animals exposed to LPS (1.5 mg/kg). We conclude that LPS sensitizes cardiac beta-adrenoceptors by recruiting functionally active beta2-adrenoceptors, but the amplification of tachycardia occurs only when both beta1- and beta2-adrenoceptors are concomitantly activated. The pithed rat may serve as a model to examine the beta-adrenoceptor supersensitivity in vivo.
在从遭受脓毒性休克的大鼠分离出的心房中,已证实存在β-肾上腺素能受体介导的变时性反应超敏现象。我们开展这项研究是为了探究细菌内毒素/脂多糖(LPS)是否也会在体内影响β-肾上腺素能受体激动剂诱导的大鼠心率增加。在脊髓切断和迷走神经切断的大鼠中,非选择性β-肾上腺素能受体激动剂异丙肾上腺素(0.05 - 0.15 nmol/kg)以及处于β1-肾上腺素能受体高亲和力和低亲和力状态的激动剂,即普瑞特罗(0.3 - 3 nmol/kg)和(±)-4-[3-[(1,1-二甲基乙基)氨基]-2-羟基丙氧基]-1,3-二氢-2H-苯并咪唑-2-酮(CGP 12177;3 - 6 nmol/kg),以及β2-肾上腺素能受体激动剂非诺特罗(1 - 5 nmol/kg),可使心率增加50至60次/分钟。在持续输注血管加压素的情况下,给予LPS(0.4、1和1.5 mg/kg)剂量依赖性地增强了对异丙肾上腺素、普瑞特罗和非诺特罗的变时性反应(分别增加80%、50%和100%),但对CGP 12177无此作用。β2-肾上腺素能受体拮抗剂erythro-(±)-1-(7-甲基茚满-4-基氧基)-3-异丙氨基丁-2-醇(ICI 118551 0.1 μmol/kg)在非内毒素条件下不影响异丙肾上腺素、非诺特罗和普瑞特罗的变时性反应,但可消除LPS(1.5 mg/kg)所产生的心动过速增强作用。β1-肾上腺素能受体拮抗剂(±)-2-羟基-5-[2-[[2-羟基-3-[4-[1-甲基-4-(三氟甲基)-1H-咪唑-2-基]-苯氧基]丙基]-氨基]乙氧基]-苯甲酰胺CGP 2071(2A;0.1 μmol/kg)几乎完全降低了对照组大鼠以及暴露于LPS(1.5 mg/kg)的动物中异丙肾上腺素、非诺特罗和普瑞特罗的变时性效应。我们得出结论,LPS通过募集功能活跃的β2-肾上腺素能受体使心脏β-肾上腺素能受体敏感化,但心动过速的增强仅在β1-和β2-肾上腺素能受体同时被激活时才会发生。脊髓切断的大鼠可作为体内检测β-肾上腺素能受体超敏性的模型。